- GlobeNewswire•15 days ago
NEW YORK, Oct. 11, 2016-- Ohr Pharmaceutical, Inc., an ophthalmology research and development company, today announced that the company has been selected to present at the 2016 Ophthalmology Innovation ...
- GlobeNewswire•last month
PRESS RELEASE TiGenix Appoints Dr. June Almenoff to its Board of Directors Leuven (BELGIUM) - September 22, 2016, 07:00h CET - TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company ...
- Capital Cube•last month
Categories: Yahoo Finance Get free summary analysis Ohr Pharmaceutical, Inc. reports financial results for the quarter ended June 30, 2016. Analysis Summary numbers: Revenues of USD 0 million, Net Earnings of USD -7.70 million. The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless. OHRP-US‘s earnings ... Read more (Read more...)
Ohr Pharmaceutical, Inc. (OHRP)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||1.80 x 100|
|Day's Range||3.35 - 3.65|
|52wk Range||2.44 - 6.56|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-4.56|
|Avg Vol (3m)||103,861|
|Dividend & Yield||N/A (N/A)|